Merck’s Zostavax draws new litigation from patients alleging contract Shingles 7/21/17 FiercePharma

Discussion in 'Health News' started by GG, Jul 27, 2017.

  1. GG

    GG Well-Known Member

    Even as Merck & Co. confronts the prospect of a tough market competitor in GlaxoSmithKline’s Shingrix, the drugmaker’s shingles vaccine Zostavax faces a growing challenge in court.

    Eighteen patients have filed a liability lawsuit against Merck, alleging the company produced and sold an “unreasonably dangerous vaccine” that caused serious injuries after vaccination. Hailing from a range of states including Louisiana, South Carolina, Tennessee, Michigan and Wisconsin, the plaintiffs filed their suit in Merck’s home state of New Jersey.